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ABSTRACT: A recent untargeted metabolomics investigation
into the chemical profile of 10 organic extracts from cf.
Symploca spp. revealed several interesting chemical leads for
further natural product drug discovery. Subsequent target-
directed isolation efforts with one of these, a Panamanian
marine cyanobacterium cf. Symploca sp., yielded a phenethyl-
amide metabolite that terminates in a relatively rare gem-
dichlorovinylidene moiety, caracolamide A (1), along with a
known isotactic polymethoxy-1-alkene (2). Detailed NMR and
HRESIMS analyses were used to determine the structures of
these molecules, and compound 1 was confirmed by a three-
step synthesis. Pure compound 1 was shown to have in vitro
calcium influx and calcium channel oscillation modulatory activity when tested as low as 10 pM using cultured murine cortical
neurons, but was not cytotoxic to NCI-H460 human non-small-cell lung cancer cells in vitro (IC50 > 10 μM).
Halogenated secondary metabolites are known to existquite widely in Nature, with more than 5000 of these
having been described previously.1 Perhaps unsurprisingly,
marine natural products have a higher incidence of halogen
atoms than those obtained from terrestrial or freshwater
organisms.2,3 Compared to the total number of halogenated
natural products reported, however, polyketides and lipids that
contain terminal halogenation are relatively rare.4 Several
halogenated polyketides and lipids have been isolated from
marine cyanobacteria, such as the calcium channel oscillation
modulators credneramides A and B, sodium channel blockers
jamaicamide A, janthielamide A, and kimbeamides A−C, and in
vitro cancer cell toxins veraguamides A, B, K, and L.5−9
Pitiamides A and B are another family of fatty acid amides that
terminate with a vinyl chloride moiety, and they were also
shown to modulate intracellular calcium levels.10,11 Even more
rare in Nature are those that contain gem-dichlorovinylidene
moieties, currently numbering only about 30 in the Dictionary
of Natural Products (http://dnp.chemnetbase.com) database.
The presence of such an atypical functional group, particularly
among plant natural products, may in some cases be an
experimental artifact. Chloroform can form a reactive
dichlorocarbene species under certain conditions and lead to
the formation of gem-dichlorovinylidene moieties.12 However,
marine natural products, such as the taveunamides, mutafuran,
(Z)- and (E)-antazirine, and several analogous azirinecarbox-
ylates that were isolated from the sponge Dysidea f ragilis, have
been shown to contain gem-dihalovinylidene moieties compris-
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ing only bromine or chlorine or atoms of each element, thus
supporting their natural biosynthetic origins.4,13
Chemical profiling of extracts produced from 10 morpho-
logically identified Symploca spp., comprising two field-
identified collections from American Samoa, one from Saipan,
six from Panama, and one grown in the laboratory from the
Pasteur Culture Collection (PCC8002), was achieved using
LC-MS/MS and molecular networking untargeted metabolo-
mics (Figure 1, A).14 This revealed several candidates for MS-
based targeted natural product discovery.14 For example, after
utilization of the Global Natural Products Social Molecular
Network (GNPS at http://gnps.ucsd.edu) Web site to correlate
these data, it was found that several clusters of secondary
metabolites were present with unique or very limited
distribution among these taxa. It was hypothesized that the
biosynthesis of these molecules might have a role in mediating
specific biological interactions, and thus they were prioritized
for natural product drug discovery efforts. Accordingly, the
secondary metabolites of the cyanobacterium cf. Symploca sp.
PAB-6APR13-2, collected near Punta Caracol, Panama, were
selected for targeted isolation and structure elucidation (Figure
1, B). Because this discovery process was based on LC-MS and
MS/MS data, it was clear from the outset that one of the
targeted molecules, compound 1, had an isotopic signature
indicative of the presence of two chlorine atoms. This fact along
with its candidate molecular formula of C16H21Cl2NO
suggested its novelty compared to known compounds in the
Dictionary of Natural Products and MarinLit (http://pubs.rsc.
org/marinlit/) databases. In addition, a second metabolite was
isolated in the course of these investigations and was identified
by comparison of HRESIMS, specific rotation, and 1H and 13C
NMR data with literature values as the previously reported
isotactic polymethoxy-1-alkene 4(S),6(S),8(S),10(S),12(S),14-
(R),16(R),18(R),20(R),22(R)-decamethoxyheptacos-1-ene
(2).15−17
■ RESULTS AND DISCUSSION
Structure Elucidation. Compound 1 was determined to
have the molecular formula C16H21Cl2NO based on the sodium
adduct ion peak in the HRESIMS at m/z 336.08983 [M +
Na]+. This molecular formula indicated six inherent degrees of
unsaturation and, because of an isotopic pattern of m/z 336/
Figure 1. (A) LC-MS/MS-derived molecular network of extracts and systematically produced VLC fractions from 10 cf. Symploca spp. For more
details about the generation of this network, see ref 14. (B) Expanded region from the top-right corner of panel A, made to highlight the cluster that
contains caracolamide A (1) along with an organism extract legend.
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338/340 in a ratio of 9:6:1, supported the occurrence of two
chlorine atoms in the molecule. Analysis of the 1H NMR
spectrum of 1 in CD3OD revealed several methylene groups,
one of which, CH2-2 [δH 2.14, t (J = 7.5 Hz); δC 36.9], formed
a terminus for an acyl chain spin system. Following this, four
more methylene units were determined through sequential
COSY correlations from CH2-2 to CH2-3 [δH 1.57, pent (J =
7.5 Hz); δC 26.7], then to CH2-4 (δH 1.29, m; δC 29.6) and
CH2-5 [δH 1.43, pent (J = 7.5 Hz); δC 28.8], and finally to
CH2-6 [δH 2.17, q (J = 7.4 Hz); δC 30.4]. The protons of C-6
had COSY correlations to an olefinic methine proton at δH 5.96
[t (J = 7.4 Hz); δC 131.5 (CH-7)]. The CH2-6 protons also
showed HMBC correlations to CH-7 as well as to a relatively
shielded nonprotonated olefinic carbon at δC 120.7 (C-8).
Considering the molecular formula of 1, the chemical shifts of
CH-7 and C-8 were indicative of a gem-dichlorovinylidene
moiety.4,18 Finally, the CH2-2 and CH2-3 protons showed
cross-peaks by HMBC with an amide-type carbonyl carbon at
δC 176.1 (C-1), establishing substructure 1a (Figure 2).
The 1H NMR spectrum of 1 also exhibited five aromatic
protons at δH 7.18−7.26, consistent with a monosubstituted
phenyl ring. The phenyl protons ortho to the substitution, CH-
4′ and CH-8′ [δH 7.21, d (J = 7.5 Hz), 2H; δC 129.8],
possessed clear HMBC correlations to a benzylic methylene
group [CH2-2′, δH 2.79, t (J = 7.3 Hz); δC 36.5]. The latter
protons were adjacent to another deshielded methylene group
by COSY correlations [CH2-1′, δH 3.41, t (J = 7.3 Hz); δC
41.9]. Furthermore, the protons of C-1′ showed HMBC
correlations to the fully substituted carbon of the phenyl ring
(C-3′, δC 140.5). The chemical shift of C-1′ at δC 41.9 was
indicative of its direct attachment to a nitrogen atom, and this
was confirmed by an HMBC correlation between CH2-1′ and
C-1, thus defining a phenethylamide moiety (1b) and
connecting the two partial structures (Figure 2). Furthermore,
the 1H NMR spectrum of 1 recorded in CDCl3 included one
additional proton signal at δH 5.34 for the amide proton and
thus completed the structural characterization of compound 1,
named here as caracolamide A.
Total Synthesis. To confirm the structure of compound 1
and provide material for further biological investigation, a three-
step total synthesis was designed (Figure 3). The scheme
initiated with the formation of an amide bond between two
commercially available starting materials: 2-phenylethylamine
(3) and 7-hydroxyheptanoic acid. This is analogous to the
initiation of the synthesis developed for the structurally related
credneramides A and B.19 The resulting intermediate alcohol
(4) was oxidized with Dess-Martin periodinane (DMP) to form
the corresponding aldehyde (5), and this was converted into
the final product (1) by Wit t ig react ion with
dichloromethylenetriphenylphosphorane.20,21 The purified re-
action yields obtained for each of the three steps to form 4, 5,
and 1 were 20%, 99%, and 62%, respectively, providing an
overall yield of 12% (excluding recoverable starting materials).
Synthetic compound 1 had 1H and 13C NMR spectra, along
with HRESIMS data, that matched those of the isolated natural
product.
Biological Evaluation. Pure compounds 1 and 2 were
evaluated for their cytotoxic activity toward NCI-H460 non-
small-cell lung cancer cells in vitro; however, neither of these
molecules was found to be cytotoxic (IC50 > 10 μM).
Structurally, 1 is related to a few other cyanobacterial natural
products, including credneramide A and santacruzamate A.5,22
These molecules each feature a 2-phenethylamide moiety with
a modified fatty acid group. In the case of credneramide A,
there is also a terminal vinyl chloride moiety installed during
the biosynthesis of its presumed precursor molecule, credneric
acid.5 Because credneramide A and its analogues have been
shown to inhibit spontaneous calcium oscillations in murine
cerebrocortical neurons, caracolamide A (1) was evaluated in
Figure 2. Selected correlations used to determine the two partial
structures of caracolamide A (1). Bolded bonds represent correlated
protons in the COSY spectrum. Arrows represent cross-peaks from the
1H−13C HMBC spectrum.
Figure 3. Synthetic scheme for preparation of caracolamide A (1). HATU: 1H-1,2,3-triazolo[4,5-b]pyridinium, 1-[bis(dimethylamino)methylene]-,
hexafluoro-phosphate(1-), 3-oxide (9CI). DIPEA: N,N-diisopropylethylamine. DMF: dimethylformamide. Reagents and conditions: (a) 7-
hydroxyheptanoic acid (1 equiv), HATU (1.1 equiv), DIPEA (1 equiv), rt in 4:1 DMF/CH2Cl2; (b) Dess-Martin periodinane (1.5 equiv), NaHCO3
(4 equiv), rt in CH2Cl2; (c) triphenylphosphine (1 equiv), CHCl3 (1 equiv), n-BuLi (1.1 equiv), in THF at −78 C then rt.
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this assay system. Remarkably, at subnanomolar concentrations,
caracolamide A displayed statistically significant effects on
calcium oscillation amplitude in neocortical neurons (Table 2
and Figure 4). The frequency of calcium oscillations observed
during the same biological assay, however, was not statistically
different at any of the concentrations tested (Supporting
Information).
Because metabolite 1 is a phenethylamide, the commercially
available and structurally simpler molecule 2-phenylethylamine
(3) was also tested in this bioassay and elicited similar effects at
the same concentrations as 1 (Supporting Information). The
modulatory effects observed on calcium oscillation amplitude
suggest a profound regulation of neuronal function and are
further predictive of sodium channel blocking and neurotoxic
activities. Additional investigations will be necessary to confirm
these hypotheses for metabolite 1; however, compound 3 is a
known neuroactive agent and “trace amine”, indicating that it is
present at much lower concentrations than the more common
biogenic amines such as serotonin or dopamine.23,24 However,
the ion channel modulating properties observed for the amide
(1) and the primary amine (3) may be unrelated, as these
molecules will have different charge states and attendant
physical properties under the conditions of the biological assay.
Alternatively, it may be that the biological activity of 1 is related
to that of pitiamides A and B, two fatty acid amides with
terminal alkyl halide groups.10,11 Pitiamides A and B were
previously shown to modulate plasma membrane potentials,
increase intracellular calcium levels, and have low μM IC50
values against HCT116 cells.11 Further pharmacological studies
using the pitiamides, 1, and other structurally related molecules
will be necessary to make more meaningful comparisons
between these agents.
■ CONCLUSIONS
The utilization of MS/MS-based molecular networking
facilitated the targeted isolation and structural characterization
of a new natural product, caracolamide A (1), from the
Panamanian cyanobacterium cf. Symploca sp. (Collection code
PAB-6APR13-2). The relatively simple molecular architecture
of compound 1 allowed for its three-step total synthesis, and
this both confirmed the structure of 1 and provided material for
biological testing. This new metabolite has some structural
similarity to the credneramides and pitiamides and was further
demonstrated to share the biological properties of these
molecules by modulating calcium channel function in murine
cerebrocortical neurons in vitro. Future studies using syntheti-
cally produced caracolamide A (1), as well as analogues created
via similar synthetic procedures, will enable the development of
a broader knowledge of its biological and ecological properties.
■ EXPERIMENTAL SECTION
General Experimental Procedures. A JASCO P-2000 polar-
imeter was used to measure optical rotations at 25 °C. Ultraviolet and
visible (UV−vis) spectra were recorded using a Beckman Coulter DU
800 spectrophotometer. Infrared (IR) spectra were obtained on a
Thermo Nicolet IT 100 FT-IR (Thermo Fisher Scientific). A Bruker
Avance III 600 NMR spectrometer equipped with a Bruker
cryoplatform and a 5 mm inverse detection triple resonance (H−C/
N/D) cryoprobe with z-gradients was used to record NMR data at 298
K using standard Bruker pulse sequences. Additional NMR data were
obtained on a JEOL ECZ 500 NMR spectrometer equipped with a 3
mm inverse detection probe with z-gradients and a Varian vx 500
NMR equipped with a Varian XSens 2 channel (1H/13C) NMR cold
Table 1. 1H and 13C NMR Spectroscopic Data of
Caracolamide A (1) in CD3OD
a
position δC, type δH, mult (J in Hz) HMBC
b
1 176.1, C
2 36.9, CH2 2.14, t (7.5) 1, 3, 4
3 26.7, CH2 1.57, t (7.5) 1, 2, 4, 5
4 29.6, CH2 1.29, m 2, 3, 6
5 28.8, CH2 1.43, pent (7.5) 3, 6, 7
6 30.4, CH2 2.17, q (7.4) 4, 5, 7, 8
7 131.5, CH 5.96, t (7.4) 5
8 120.7, C
1′ 41.9, CH2 3.41, t (7.3) 1, 2′, 3′
2′ 36.5, CH2 2.79, t (7.3) 1′, 3′, 4′, 8′
3′ 140.5, C
4′, 8′ 129.8, CH 7.21, d (7.5) 4′, 6′, 8′
5′, 7′ 129.5, CH 7.27, t (7.5) 3′, 5′, 7′
6′ 127.3, CH 7.18, t (7.5) 4′, 8′
aData recorded at 298 K, 600 MHz (1H) and 150 MHz (13C).
Assignments supported by 2D NMR. bHMBC correlations, optimized
for 8 Hz, are from proton(s) to the indicated carbon.
Table 2. Statistical Analysis for Caracolamide A (1)-Induced
Changes in Spontaneous Ca2+ Oscillations in Neocortical
Neurons
dosea
total no. of
oscillationsb
mean amplitude
of oscillations
95% CI of
amplitude
P-value of
amplitudec
baseline 359 1660 1567 to
1753
0.01 nM
[1]
282 1053 942 to 1164 0.0279
baseline 330 1883 1759 to
2007
0.1 nM
[1]
272 1103 991 to 1213 0.0085
baseline 323 1676 1560 to
1792
1 nM [1] 266 894 803 to 984 0.0060
baseline 361 1781 1684 to
1878
10 nM
[1]
324 1388 1286 to
1489
0.0191
baseline 363 1464 1387 to
1541
100 nM
[1]
334 887 827 to 947 0.0111
baseline 353 1332 1250 to
1413
1000 nM
[1]
330 727 678 to 776 0.0069
baseline 214 2307 2159 to
2456
controld 179 2430 2238 to
2623
0.1803
aBaseline amplitude was calculated as peak minus trough for each
oscillation during 120 s baseline reading. Compound dose amplitude
was calculated as peak minus trough for each oscillation during 120 s
reading following compound addition. Amplitudes from 10 replicates
were pooled. bThe total number of oscillations observed during the 2
min before and after application of caracolamide A (1) was determined
to not be significantly different (Supporting Information). cA two-
tailed paired t test was performed to assess differences in oscillation
amplitude between the means from before and after application of
caracolamide A (1). dSolvent control (DMSO, 0.04% final
concentration) was performed in cortical culture on a different date
from the other assays.
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probe optimized for direct observe 13C NMR. All NMR data were
calibrated to the solvent residual peak(s) observed in the 1H and 13C
NMR spectra (C6D6 δH 7.16, δC 128.06; CDCl3 δH 7.26, δC 77.16;
CD3OD δH 3.31, δC 49.00).
25 Nominal mass resolution LC-MS data
were collected using an HPLC comprising a Thermo Finnigan
Surveyor PDA Plus detector, Autosampler Plus, and LC Pump Plus
coupled to an LCQ Advantage Plus mass spectrometer (all Thermo
Fisher Scientific), with a Phenomenex Kinetex C18 100 × 4.6 mm × 5
μm analytical column installed. Exact mass HRESIMS data were
recorded using an Agilent 6530 Accurate-Mass QTOF mass
spectrometer in positive ion mode. Semipreparative HPLC was
performed using a Kinetex C18 150 × 10.0 mm × 5 μm
semipreparative column (Phenomenex) connected to an HPLC
system comprising a Thermo Dionex UltiMate 3000 pump, RS
autosampler, RS diode array detector, and automated fraction collector
(all Thermo Fisher Scientific). HPLC-grade CH3CN was purchased
from Thermo Fisher Scientific, and HPLC-grade H2O was obtained by
filtration using a Milli-Q Direct water purification system (Millipore).
Deuterated NMR solvents were purchased from Cambridge Isotope
Laboratories.
Organism Collection and Identification. Small colonies of a
morphologically identified cf. Symploca species (e.g., reddish-purple
color and a stiff “paintbrush” shape) were obtained in April 2013 by
scuba diving to 3−6 m at Punta Caracol (9°22′24.0″ N 82°18′06.0″
W), Bocas del Toro, Panama. The organism was preserved in 0.5 L of
1:1 seawater−2-propanol solution, transported to the laboratory in San
Diego, CA, USA, and frozen at −20 °C until extraction.
Extraction, Molecular Networking, and Isolation. The raw
biomass of this sample (88.2 g) was extracted exhaustively with 2:1
CH2Cl2−MeOH to yield 1.5 g of organic extract (A2143) after solvent
evaporation. This material was fractionated by vacuum liquid
chromatography (VLC) over silica gel to produce nine subfractions
of increasing polarity by elution with 300 mL each using a step
gradient of hexanes (A2143A; 50.4 mg), 9:1 hexanes−EtOAc
(A2143B; 54.0 mg), 4:1 hexanes−EtOAc (A2143C; 65.4 mg), 3:2
hexanes−EtOAc (A2143D; 76.8 mg), 2:3 hexanes−EtOAc (A2143E;
50.9 mg), 1:4 hexanes−EtOAc (A2143F; 58.0 mg), 100% EtOAc
(A2143G; 29.1 mg), 3:1 EtOAc−MeOH (A2143H; 235.8 mg), and
100% MeOH (A2143I; 722.4 mg). These subfractions were analyzed
by nominal mass LC-MS as described previously.14 Briefly, samples
were individually preprocessed using C18 SPE cartridges by application
of 0.3 mg of sample and elution with 1 mL of CH3CN. A 10 μL aliquot
of each sample was injected into the LC-MS and eluted at 0.7 mL/min
by a gradient program of CH3CN−H2O (0.1% formic acid modifier):
30% for 5 min to 99% in 17 min, held for 3 min, to 30% in 1 min, and
held for 4 min. The mass spectrometer was set to observe m/z 190−
2000 in positive ESI mode and with an automated data-dependent
MS/MS scan enabled. The resulting data were utilized to create a
molecular network of 10 extracts from morphologically identified
samples of distinct cf. Symploca spp. for the purpose of dereplication
and molecular targeting.14 Accordingly, fractions A2143E−G were
selected for further isolation studies because they had network nodes
and clusters that were unique to this analysis.
Fractions A2143E and A2143F were each further purified by RP-
HPLC using a Phenomenex Synergi Fusion C18 column (250 × 10.00
mm × 4 μm) and gradient solvent system (65% CH3CN−H2O for 5
min, linear gradient to 80% CH3CN in 15 min, linear gradient to 100%
CH3CN in 5 min) at 4.0 mL/min. Subfractions from each were
analyzed and combined to yield compound 1 (tR = 7.6 min; 0.7 mg,
0.0008% w/w extraction yield).
An aliquot of fraction A2143G (21 mg) was further separated using
a GracePure SPE C18-Max cartridge with a step gradient of solvents:
Figure 4. Representative time and concentration response relationships for caracolamide A (1)-induced changes in spontaneous Ca2+ oscillations in
neocortical neurons. (A) Tetrodotoxin (1 μM) was used as a negative control. (B−G) Results from testing of 10 pM through 1 μM of compound 1,
as individually indicated. (H) Veratridine (30 μM) was used as a positive control. Representative data shown from two experiments with five
replicates per dose per experiment. Statistical analysis is presented in Table 2.
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65% CH3CN−H2O (A2143G.1; 8.6 mg), 75% CH3CN−H2O
(A2143G.2; 5.8 mg), 85% CH3CN−H2O (A2143G.3; 0.5 mg), 95%
CH3CN−H2O (A2143G.4; 1.0 mg), CH3CN (A2143G.5; 0.5 mg),
and MeOH (A2143G.6; 2.8 mg). Fraction A2143G.1 was pooled with
A2143G.2 and subjected to RP-HPLC purification using a
Phenomenex Kinetex C18 column (150 × 10.00 mm, 5 μm) and
gradient solvent system (65% CH3CN−H2O for 5 min, linear gradient
to 80% CH3CN in 15 min, linear gradient to 100% CH3CN in 5 min)
at 4.0 mL/min to yield compound 2 (tR = 17.6 min; 1.8 mg, 0.02%
w/w extract yield). Spectroscopic, spectrometric, and specific rotation
data {[α]23D +7.30 (c 0.15, MeOH)]} obtained for compound 2
matched corresponding literature values {e.g., [α]25D +4.73 (c 0.43,
CHCl3)]} for the isotactic polymethoxy-1-alkene 4(S),6(S),8(S),10-
(S),12(S),14(R),16(R),18(R),20(R),22(R)-decamethoxyheptacos-1-
ene.15−17
Caracolamide A (1): slightly yellow, oily residue; UV (MeOH) λmax
(log ε) 201 (4.31), 280 (2.85) nm; IR (film) νmax 3301, 2927, 2857,
1643, 1546, 1457, 1369, 879, 740, 698 cm−1; 1H NMR and 13C NMR,
Table 1; HRESIMS m/z 336.08983 [M + Na]+ (calcd for
C16H21Cl2NONa, 336.08924); LR MS/MS m/z 313.97 [M + H]
+,
121.81, 105.02.
Synthesis of 7-Oxo-N-phenethylheptanamide (4). To a
solution of 2-phenylethylamine (3; 2.487 g, 20.52 mmol; Sigma-
Aldrich), 7-hydroxyheptanoic acid (1.5 g, 10.26 mmol; OxChem), and
HATU (4.29 g, 11.29 mmol; Sigma-Aldrich) in dimethylformamide
(DMF; 6.84 mL)/CH2Cl2 (27.4 mL) was quickly added DIPEA
(1.792 mL, 10.26 mmol). The reaction mixture was stirred overnight
at room temperature (rt) to generate compound 4. The mixture was
worked up by addition of excess EtOAc, washed three times with 1 M
HCl and then saturated sodium bicarbonate and brine. The organic
layer was dried using anhydrous sodium sulfate, filtered, and
evaporated under reduced pressure. The residue was purified on
normal-phase silica flash chromatography using a gradient of 0−10%
MeOH in EtOAc to obtain 4 (515.3 mg; 2.07 mmol; 20% yield).
7-Hydroxy-N-phenethylheptanamide (4): 1H NMR (500 MHz) δ
7.30 (t, J = 7.4 Hz, 2H), 7.22 (m, 1H), 7.19 (m, 2H), 3.60 (t, J = 6.5
Hz, 2H), 3.50 (q, J = 6.9 Hz, 2H), 2.80 (t, J = 6.9 Hz, 2H), 2.12 (t, J =
7.4 Hz, 2H), 1.59 (pent, J = 7.4 Hz, 2H), 1.54 (pent, J = 7.4 Hz, 2H),
1.33 (m, 2H); 13C NMR (125 MHz) δ 173.2, 139.0, 128.9, 128.7,
126.6, 62.8, 40.6, 36.7, 35.8, 32.6, 29.0, 25.7, 25.5; HRESIMS m/z
250.1800 [M + H]+ (calcd for C15H24NO2, 250.1802).
Synthesis of 7-Oxo-N-phenethylheptanamide (5). To a
solution of 4 (68 mg, 0.273 mmol; Sigma-Aldrich) and sodium
bicarbonate (92 mg, 1.091 mmol; Sigma-Aldrich) in CH2Cl2 (1.364
mL) was added DMP (173 mg, 0.409 mmol) in one portion at rt. The
reaction mixture was stirred at this temperature for 1 h to generate 5.
The reaction was monitored by normal-phase silica TLC for the
conversion of 4 (5:1 CH2Cl2−acetone; Rf = 0.33) to 5 (5:1 CH2Cl2−
acetone; Rf = 0.50). The reaction mixture was worked up by dilution
with 15 mL of EtOAc and the addition of 5 mL of a saturated solution
of sodium thiosulfate in H2O, then extracted twice with 10 mL of
EtOAc, washed with brine, dried over MgSO4, filtered, and
concentrated under vacuum. After workup, the crude material was
determined to be of high enough purity by NMR and LC-MS to carry
forward in the synthesis (67.5 mg; 0.273 mmol; 99% yield).
7-Oxo-N-phenethylheptanamide (5): 1H NMR (500 MHz,
CDCl3) δ 9.73 (t, J = 1.6 Hz, 1H), 7.30 (m, 2H), 7.22 (m, 1H),
7.19 (m, 2H), 3.50 (q, J = 7.0 Hz, 2H), 2.80 (t, J = 7.0 Hz, 2H), 2.42
(td, J = 7.4, 1.6 Hz, 2H), 2.11 (t, J = 7.4 Hz, 2H), 1.61 (q, J = 7.4 Hz,
2H), 1.60 (q, J = 7.4 Hz, 2H), 1.29 (m, 2H); 13C NMR (125 MHz,
CDCl3) δ 202.7, 172.9, 139.0, 128.8, 128.7, 126.6, 43.7, 40.6, 36.5,
35.7, 28.7, 25.4, 21.7; HRESIMS m/z 248.1642 [M + H]+ (calcd for
C15H22NO2, 248.1645).
Synthesis of 8,8-Dichloro-N-phenethyloct-7-enamide (Car-
acolamide A; 1). To a solution of PPh3 (90 mg, 0.342 mmol; Sigma-
Aldrich) and CHCl3 (0.0274 mL, 0.342 mmol) in tetrahydrofuran
(THF; 1.315 mL) at −78 °C was added dropwise n-BuLi (0.147 mL,
0.368 mmol) to generate dichloromethylenetriphenylphosphorane.
The reaction turned a dark brown-orange color and was stirred for 15
min at this temperature before a solution of 5 (65.1 mg, 0.263 mmol)
in THF (0.3 mL) was added dropwise. The reaction was stirred at −78
°C for 30 min, at which time the dry ice bath was removed and the
reaction was stirred for an additional 1 h. The mixture was diluted in
EtOAc (5 mL) and then quenched with saturated aqueous NH4Cl (5
mL) and H2O (5 mL). The layers were partitioned, and the aqueous
phase was extracted with EtOAc (3 × 5 mL). The combined organic
layers were washed with brine (10 mL), dried over MgSO4, filtered,
and concentrated under vacuum. The crude reaction product was
purified via normal-phase silica flash chromatography (0−25% EtOAc
in hexanes) to afford pure 1 (51 mg, 0.162 mmol, 62% yield).
Characterization data of the synthesized compound 1 exactly matched
that of the natural product.
In Vitro Cytotoxicity Test Protocols. Samples were evaluated for
cytotoxicity to NCI-H460 cells according to previously published
protocols with the exception of the concentrations studied.26 Briefly,
180 μL of suspended cells were added to each well of several 96-well
plates at 3.33 × 104 cells/mL in RPMI 1640 medium with 10% fetal
bovine serum (FBS) and 1% penicillin−streptomycin. The plates were
incubated overnight at 37 °C in a 5% CO2 chamber before application
of test samples. Samples were dissolved in DMSO and diluted in
RPMI 1640 medium without FBS to final concentrations of 1 or 10
μg/mL for crude samples, 10 final concentrations with 3-fold serial
dilutions starting from 100 μg/mL, screened in duplicate, for pure
compounds. Doxorubicin (1 μg/mL) and DMSO in RPMI 1640
without FBS were used as positive and negative controls, respectively.
Plates were incubated for 48 h and then stained with MTT (thiazolyl
blue tetrazolium bromide 98%; Sigma-Aldrich) prior to being
measured on a ThermoElectron Multiskan Ascent plate reader
(Thermo) at 630 and 570 nm. Dose−response curves were generated
using nonlinear regression in GraphPad Prism computer software.
Cerebrocortical Neuron Culture. Cerebrocortical neurons were
harvested and cultured according to previously described proto-
cols.27,28 Briefly, Swiss-Webster gravid dams were euthanized by CO2
asphyxiation and embryonic day 16 mice were removed under sterile
conditions. Animal care and handling complied with protocols
approved by the Creighton University Institutional Animal Care and
Use Committee and employed measures to minimize pain and
discomfort. Cerebrocortices were dissected, stripped of meninges,
minced, and incubated with trypsin for 25 min at 37 °C. Cells were
dissociated by trituration in isolation buffer containing soybean trypsin
inhibitor and DNase, centrifuged, and resuspended in Eagle’s minimal
essential medium with Earle’s salt (MEM) supplemented with 1 mM
L-glutamine, 10% FBS, 10% horse serum, 100 IU/mL penicillin, and
0.10 mg/mL streptomycin (pH 7.4). Cells were plated onto poly-L-
lysine-coated 96-well (9 mm), clear-bottomed, black-well culture
plates (MidSci) at a density of 1.5 × 105 cells/well. Cells were then
incubated at 37 °C in a 5% CO2 and 95% humidity atmosphere.
Cytosine arabinoside (ARA-C; 10 μM) was added to the culture
medium 24 h after plating, to prevent proliferation of non-neuronal
cells. From day 4 in vitro, culture media was changed every other day
using a serum-free growth medium containing neurobasal medium
supplemented with B-27, 100 IU/mL penicillin, 0.10 mg/mL
streptomycin, and 0.2 mM L-glutamine.
In Vitro Intracellular Ca2+ Channel Oscillation Monitoring
Protocols. Cerebrocortical neuron cultures were used for [Ca2+]
measurements at day 12 in vitro (DIV12) as previously described.28
Briefly, the growth medium was removed and replaced with dye
loading medium (100 μL per well) containing 4 μM fluo-3 AM and
0.04% pluronic acid in Locke’s buffer (8.6 mM HEPES, 5.6 mM KCl,
154 mM NaCl, 5.6 mM glucose, 1.0 mM MgCl2, 2.3 mM CaCl2,
0.0001 mM glycine, pH 7.4). After 1 h of incubation in dye loading
medium, the neurons were washed four times in fresh Locke’s buffer
(180 μL per well) using an automated microplate washer (Bio-Tek
Instruments Inc.) and transferred to a FLIPR II (Molecular Devices).
Cells were excited at 488 nm, and Ca2+-bound fluo-3 emission was
recorded at 515−575 nm at 0.5 s intervals. After recording baseline
fluorescence for 2 min, 20 μL of 10× concentrations of compounds
was added to wells at a rate of 20 μL/s, and the fluorescence was
monitored for an additional 2 min. GraphPad Prism 7 software was
used to analyze time and concentration−response relationships. Fluo3
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fluorescence was expressed as Fmax − F0, where Fmax is the maximum
and F0 is the baseline fluorescence measured in each well.
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